Skip to main content
ST PHARM CO., LTD. logo

ST PHARM CO., LTD. — Investor Relations & Filings

Ticker · 237690 ISIN · KR7237690003 KO Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2023-07-04 Major Shareholding Noti…
Country KR South Korea
Listing KO 237690

About ST PHARM CO., LTD.

https://www.stpharm.co.kr/en

ST PHARM CO., LTD. is a global Contract Development and Manufacturing Organization (CDMO) specializing in Active Pharmaceutical Ingredients (APIs). The company provides technology-driven manufacturing services for gene therapies, with core expertise in oligonucleotides and various forms of RNA (xRNA), including messenger RNA (mRNA). In addition to nucleic acid-based medicines, ST Pharm offers custom manufacturing for small molecule APIs. The company's services operate under cGMP (current Good Manufacturing Practice) standards, providing comprehensive solutions that support the entire drug development lifecycle, from research and development to commercial-scale production for its global pharmaceutical partners.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed by the National Pension Service of Korea regarding their stake in ST Pharm Co., Ltd. This type of filing is a standard regulatory requirement in South Korea (under the Capital Markets Act) when an entity's shareholding crosses specific thresholds. It details the number of shares held, changes in ownership, and the purpose of the holding. Since it is a formal regulatory disclosure of major shareholding changes, it falls under the 'Major Shareholding Notification' category.
2023-07-04 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) amendment. It details a change in contract value due to the cancellation of remaining orders following the discontinuation of a clinical trial. Since this is a specific regulatory disclosure regarding a material contract change that does not fit into categories like earnings, dividends, or board changes, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate disclosures.
2023-06-28 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. This type of filing is required under the Capital Markets Act when a person or entity acquires a significant stake (typically 5% or more) in a listed company. In the provided taxonomy, this corresponds to a 'Major Shareholding Notification'.
2023-06-02 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is an official announcement of an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, location, target audience, and purpose (NDR participation). While it mentions IR materials, the document itself is a notification of the event schedule and logistics rather than the presentation deck itself. According to the 'Menu vs Meal' rule, this is an announcement of an event/report, fitting the criteria for a Regulatory Filing (RNS) or a general announcement.
2023-05-24 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is an official announcement regarding an upcoming Investor Relations (IR) event (Corporate Day 2023). It provides details such as the date, location, purpose, and key topics to be discussed. While it contains some summary information about the company's mRNA platform and clinical progress, it is fundamentally a notice of an event and a disclosure of the availability of IR materials, fitting the definition of a Regulatory Filing (RNS) or a general corporate announcement regarding IR activities.
2023-05-18 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for ST Pharm Co., Ltd. (에스티팜(주)) for the first quarter of 2023 (제16기 1분기). It contains detailed financial data, business operations, production capacity, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.